SUREmAb™

Monoclonal Antibody Development, the Way it's Meant to Be.

Simple, secure, and streamlined from cell line development (CLD) to drug substance release.

SUREmAb preemptively navigates technical hurdles for exceptional performance, delivering high titers (up to 10 g/L) with a streamlined, lower-cost workflow. Thanks to this preset offer, your simple mAb development is made SURE, while accelerating timelines and maximizing ROI.

- Transfection to high-performing RCB in as little as 9 weeks
- Drug substance release in as little as 11 months
- Efficient processes for high titers and exceptional yield
- Innovation with alleviation of royalties when you manufacture with KBI Biopharma

Join a Legacy of Success

SUREmAb is built on the power of our SUREtechnology Platform™ powered by Selexis®

15+
Years of mAb Development Experience

150+
Therapeutic mAb Projects

7
Commercialized mAb Therapeutics

SUREmAb™: Research Cell Bank (RCB) Generation, Simplified



For more information, visit our website: **www.kbibiopharma.com/suremab**

SUREmAb™

Transition to Manufacturing, Streamlined

Figure 1: SUREmAb provides similar performance to regular SUREtechnology Platform Process



Fig. 1 - SUREmAb compared to regular SUREtechnology Platform process. Titer profile of twelve RCB cell lines expressing an IgG1 produced in Ambr® 15 using SUREmAb platform in blue and SUREtechnology Platform in orange. Straight line represents the average value and the bands represent the SD of the twelve RCB cell lines.

Fig. 2 - SUREmAb scalability. VCD, viability (a) and productivity (b) profiles of one stable RCB expressing an IgG1 in 3 different scales: Ambr® 15, 3L and 200L bioreactors. Two chemically defined media were used: standard industry medium 1 (straight lines) and CHO-optimized medium CELLiST™ Basal CHO MX (dotted line).

Figure 2: SUREmAb provides robust cell lines shown to be scalable



Global Compliance Local Presence

Please note: The SUREmAb offer does not apply to mAb-based biosimilar projects or for any IgG shape-derived proteins that are different from an intact IgG format - including bsAbs, Fc fusions, and IgG fragments - as well as other protein classes outside of IgGs. Timeline estimates are subject to open manufacturing capacity and may vary by project.

KBI BIOPHARMA